SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics - Quaterly Results

11 Apr 2022 Evaluate
The sales figure stood at Rs. 512.12 millions for the March 2022 quarter. The mentioned figure indicates a growth of about 30.97% as compared to Rs. 391.02 millions during the year-ago period.The Total revenue for the quarter ended March 2022 of  Rs. 122.84  millions  grew by 223.35% from Rs. 37.99 millions.Operating profit surged to 109.42 millions from the corresponding previous quarter of 90.92 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 512.12 391.02 30.97 1371.27 2023.80 -32.24 1371.27 2023.80 -32.24
Other Income 0.09 0.05 80.00 0.57 0.58 -1.72 0.57 0.58 -1.72
PBIDT 109.42 90.92 20.35 156.89 472.79 -66.82 156.89 472.79 -66.82
Interest 0.07 0.33 -78.79 0.40 19.63 -97.96 0.40 19.63 -97.96
PBDT 149.78 90.59 65.34 77.89 453.16 -82.81 77.89 453.16 -82.81
Depreciation 34.83 39.41 -11.62 139.99 158.24 -11.53 139.99 158.24 -11.53
PBT 114.95 51.18 124.60 -62.10 294.92 -121.06 -62.10 294.92 -121.06
TAX -7.89 13.19 -159.82 -8.42 67.14 -112.54 -8.42 67.14 -112.54
Deferred Tax -9.88 -0.09 10877.78 -14.62 56.47 -125.89 -14.62 56.47 -125.89
PAT 122.84 37.99 223.35 -53.68 227.78 -123.57 -53.68 227.78 -123.57
Equity 406.73 406.73 0.00 406.73 406.73 0.00 406.73 406.73 0.00
PBIDTM(%) 21.37 23.25 -8.11 11.44 23.36 -51.03 11.44 23.36 -51.03

Lasa Supergenerics Share Price

8.14 0.25 (3.17%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×